Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin - Wikidata - awgldk - TriplyDB

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

http://www.wikidata.org/entity/Q27015134

about

Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma.Expression and diagnostic values of calretinin and CK5/6 in cholangiocarcinoma.Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.Hep88 mAb-initiated paraptosis-like PCD pathway in hepatocellular carcinoma cell line through the binding of mortalin (HSPA9) and alpha-enolase.Effect of taurine on the proliferation and apoptosis of human hepatocellular carcinoma HepG2 cells.High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.Carbohydrate-based materials for targeted delivery of drugs and genes to the liver.p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.Frontiers and Opportunities: Highlights of the 2 Annual Conference of the Chinese Antibody Society

P2860

Q30834745-859BE24D-4BAF-4F19-872F-9CF7D99F5101 Q33654429-8D197A8A-DA95-415D-BE7F-716457C10D21 Q33779122-2C15E2F9-E06B-49AD-BFF3-250FF35CB9F0 Q35170403-51944578-0701-494A-81F5-9EAB13B5FB8C Q35189366-35EC257C-FE2B-4984-AA3D-42F95BEC440D Q35802713-72CDAAC5-1272-460F-8FDD-BDE69C92D3ED Q36402695-6E68756F-3140-4E22-922E-34BFB26C920D Q36759405-9DF3C037-1D04-4654-82CE-5BD354D814A7 Q38555088-7E858827-5CAF-410F-A6AD-16D0C39E0EBA Q40707172-DD5B6E16-5427-434A-B8BA-FB50C5B9B049 Q58556647-A8EE1FBF-EF00-4A66-83CA-3209B06B0874

P2860

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

http://www.wikidata.org/entity/Q27015134

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@ast

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@en

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@nl

type

label

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@ast

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@en

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@nl

prefLabel

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@ast

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@en

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@nl

P1433

Q27015134-7242E63E-6557-446C-B498-D1D6AB917F66

P1476

Q27015134-B700CE94-7E18-4468-BFAF-D39543A71EF2

P2093

Q27015134-E83FB82E-D8AF-49BC-98CD-6B13B630A851

P2860

Q27015134-0953FC9D-F7C3-485D-A1FE-2D05210826C4

Q27015134-0D07AD0B-8738-4404-8041-51EA26DA9301

Q27015134-0E44FCCA-FFD7-48B3-8DF5-282FDFA105E6

Q27015134-18F36CCB-28BA-4580-ADE5-ADD67BF3EB43

Q27015134-1AFF0282-FDC6-454E-AA27-05E74159AC28

Q27015134-1FAC5204-0636-415A-82D4-63C2149EB544

Q27015134-27F6BB12-3A7F-47F4-A166-5C190BCCDFD2

Q27015134-2BD4BF05-9A46-4FBF-8604-830E9DE9F90A

Q27015134-35F88485-1710-441E-A685-DF6D48B746BA

Q27015134-3B44F86C-E777-4D67-85D2-E78CFE1B2E77

P2888

Q27015134-958A5203-227A-4EC5-870D-B5CEE947600D

P304

Q27015134-DFC3C6DB-17A8-4A17-9375-B40E25087A91

P31

Q27015134-EFB153A4-9A40-43CD-9338-70AACD7B5A75

P356

Q27015134-0E1782E7-E99E-49A4-9225-47FBD454033F

P407

Q27015134-8B4603F5-9972-4EAD-8B54-3E8F2FBE0EE5

P433

Q27015134-7D9DD573-A0FA-4E91-A153-00163CC80B1F

P478

Q27015134-CD920621-8691-4945-AA21-41ACA836AF64

P577

Q27015134-F004E65A-21E4-44BB-B786-824EED47CF01

P5875

Q27015134-88B68283-F36F-4944-AC91-B61191E79681

P6179

Q27015134-1DE61B91-D590-44AB-9490-D9FF7BC00E4A

P698

Q27015134-097830C7-3D37-42F8-86B3-5981FE5D9262

P921

Q27015134-F39EAF21-A0BA-4A8A-BE0C-13C43FC9EF2F

P932

Q27015134-0F0D5ECC-590A-4046-8383-03A1E0781C39

P356

11595360-000000000-00000

P1433

P1476

Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin

@en

P2093

Mitchell Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome

Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer

Mesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3

Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

Mesothelin targeted cancer immunotherapy

A binding domain on mesothelin for CA125/MUC16

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

P2888

11595360-000000000-00000

P304

275-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11595360-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51670053

http://www.w3.org/2001/XMLSchema#string

P6179

1005047585

http://www.w3.org/2001/XMLSchema#string

P698

21942912

http://www.w3.org/2001/XMLSchema#string

P921

P932

3198870

http://www.w3.org/2001/XMLSchema#string